synthesis of novel synthetic macrocycles containing both peptidic and polyketide-like domains
Ensemble Therapeutics, a biotechnology company in Cambridge, MA, bases its research on a new class of compounds known as Ensemblins. Ensemblins are synthetically engineered macrocycles that lie within the structural gap between small-molecule drugs and biological drugs. Ensemblins possess the biophy...
| Published: |
|
|---|---|
| Online Access: | http://hdl.handle.net/2047/d20002533 |
| Summary: | Ensemble Therapeutics, a biotechnology company in Cambridge, MA, bases its research on a new class of compounds known as Ensemblins. Ensemblins are synthetically engineered macrocycles that lie within the structural gap between small-molecule drugs and biological drugs. Ensemblins possess the biophysical properties of small-molecule drugs but the unique macrocyclic structure of Ensemblins allows for high levels of affinity and specificity for targets that are currently only
addressable with biological drugs. Ensemble Therapeutics utilizes a technology known as DNA-programmed chemistry to efficiently synthesize large, diverse libraries of Ensemblins. |
|---|